There are >10,000 species of venomous marine snails belonging to the superfamily Conoidea;one group in the superfamily are the cone snails (Conus). The general goal of this program is to develop highly selective peptide ligands derived from Conoidean venoms that have novel pharmacological specificity for various ion channel and receptor subtypes. Our laboratories have previously isolated such peptides from Conus venoms, and these have been used extensively in basic research by many laboratories, and important translational applications have emerged. In particular, Conus peptides have uncovered novel mechanisms to alleviate pain. A general goal of this Program is to develop highly selective peptide ligands for novel targets. In the next grant period, we plan to expand the general biological resource to be accessed, from the venoms of the 700 cone snails to the venomous snails in the entire family of Conoidea. The discovery activities of this Program follow a cladistic strategy that was convincingly validated in the last grant period. We believe that this discovery strategy represents a potential paradigm shift in how discovery of lead compounds from animal biodiversity will be carried out in the future. The cladistic discovery strategy is more systematic, science based and efficient than the usual procedures for """"""""bioprospecting"""""""". The Program is organized into four Cores and four Projects. Together, the Cores support all of the discovery activities of this Program, including a significant number of discovery initiatives that are not supported by any of the Projects. Furthermore, the Cores will also strengthen the scientific foundation required for extending the cladistic discovery strategy to all groups in the superfamily Conoidea. The goals of the Projects are to develop panels of highly subtype-specific peptide ligands for the nicotinic receptor family, for the sodium channel family, for the G-protein coupled-peptide receptor family, and for K channels. Each project also has specific translational applications, including the development of analgesic compounds for pain and cardioprotective compounds for myocardial infarction due to ischemia. An experimental plan to clarify basic mechanisms that underlie each translational application will be pursued. This discovery program has led to one compound already approved as a commercial drug, and many others that have either reached human clinical trials or are in advanced preclinical development. The cladistic strategy to be employed, and the larger biological resource to be accessed, should greatly accelerate the pace of discovery ultimately leading to novel translational applications. Thus, the research activities of this program interact broadly with the basic research community studying ion channels and receptors, as well as the more clinically oriented community developing novel therapeutic and diagnostic applications.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Program Projects (P01)
Project #
3P01GM048677-20S2
Application #
8724788
Study Section
Special Emphasis Panel (ZRG1-MDCN-G (40))
Program Officer
Dunsmore, Sarah
Project Start
1997-01-01
Project End
2014-06-30
Budget Start
2013-08-01
Budget End
2014-06-30
Support Year
20
Fiscal Year
2013
Total Cost
$22,496
Indirect Cost
$7,398
Name
University of Utah
Department
Biology
Type
Schools of Arts and Sciences
DUNS #
009095365
City
Salt Lake City
State
UT
Country
United States
Zip Code
84112
Richter, K; Mathes, V; Fronius, M et al. (2016) Phosphocholine - an agonist of metabotropic but not of ionotropic functions of α9-containing nicotinic acetylcholine receptors. Sci Rep 6:28660
Safavi-Hemami, Helena; Li, Qing; Jackson, Ronneshia L et al. (2016) Rapid expansion of the protein disulfide isomerase gene family facilitates the folding of venom peptides. Proc Natl Acad Sci U S A 113:3227-32
Green, Brad R; Gajewiak, Joanna; Chhabra, Sandeep et al. (2016) Structural Basis for the Inhibition of Voltage-gated Sodium Channels by Conotoxin μO§-GVIIJ. J Biol Chem 291:7205-20
Hone, Arik J; McIntosh, J Michael; Rueda-Ruzafa, Lola et al. (2016) Therapeutic concentrations of varenicline in the presence of nicotine increase action potential firing in human adrenal chromaffin cells. J Neurochem :
Espino, Samuel S; Dilanyan, Taleen; Imperial, Julita S et al. (2016) Glycine-rich conotoxins from the Virgiconus clade. Toxicon 113:11-7
Zuo, Wanhong; Xiao, Cheng; Gao, Ming et al. (2016) Nicotine regulates activity of lateral habenula neurons via presynaptic and postsynaptic mechanisms. Sci Rep 6:32937
Curtice, Kigen J; Leavitt, Lee S; Chase, Kevin et al. (2016) Classifying neuronal subclasses of the cerebellum through constellation pharmacology. J Neurophysiol 115:1031-42
Yorgason, J T; Rose, J H; McIntosh, J M et al. (2015) Greater ethanol inhibition of presynaptic dopamine release in C57BL/6J than DBA/2J mice: Role of nicotinic acetylcholine receptors. Neuroscience 284:854-64
Lee, Hee-Kyoung; Zhang, Liuyin; Smith, Misty D et al. (2015) A marine analgesic peptide, Contulakin-G, and neurotensin are distinct agonists for neurotensin receptors: uncovering structural determinants of desensitization properties. Front Pharmacol 6:11
Aman, Joseph W; Imperial, Julita S; Ueberheide, Beatrix et al. (2015) Insights into the origins of fish hunting in venomous cone snails from studies of Conus tessulatus. Proc Natl Acad Sci U S A 112:5087-92

Showing the most recent 10 out of 238 publications